Multiple Sclerosis Therapeutics
eBook - PDF

Multiple Sclerosis Therapeutics

  1. English
  2. PDF
  3. Available on iOS & Android
eBook - PDF

Multiple Sclerosis Therapeutics

About this book

This book comprehensively reviews the current state of clinical trial methods in multiple sclerosis treatment, providing investigators, sponsors and specialists with current knowledge of outcome measures and study designs for disease and symptom management. The status of the rapidly evolving field of disease-modifying drugs is presented, with emphasis on the most promising therapies currently being tested. Experts discuss disease and symptom management for MS subtypes, including neuromyelitis optica and pediatric MS. In addition, key scientific advances in MS pathology, genetics, immunology and epidemiology are presented. The fourth edition has been extensively revised, featuring more than 50% new material. All chapters have been substantially updated to provide current information on rapidly evolving topics and this volume contains 15 new chapters, reflecting the growth of the field in recent years. This book is an essential reference for practitioners caring for MS patients, investigators planning or conducting clinical trials, and clinical trial sponsors.

Frequently asked questions

Yes, you can cancel anytime from the Subscription tab in your account settings on the Perlego website. Your subscription will stay active until the end of your current billing period. Learn how to cancel your subscription.
At the moment all of our mobile-responsive ePub books are available to download via the app. Most of our PDFs are also available to download and we're working on making the final remaining ones downloadable now. Learn more here.
Perlego offers two plans: Essential and Complete
  • Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
  • Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Both plans are available with monthly, semester, or annual billing cycles.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, we’ve got you covered! Learn more here.
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Yes! You can use the Perlego app on both iOS or Android devices to read anytime, anywhere — even offline. Perfect for commutes or when you’re on the go.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Yes, you can access Multiple Sclerosis Therapeutics by Jeffrey A. Cohen,Richard A. Rudick in PDF and/or ePUB format, as well as other popular books in Medicine & Neurology. We have over one million books available in our catalogue for you to explore.

Information

Publisher
Cambridge University Press
Year
2011
Print ISBN
9780521766272
eBook ISBN
9781139153539
Edition
4
Topic
Medicine
Subtopic
Neurology

Table of contents

  1. Cover
  2. Multiple Sclerosis Therapeutics
  3. Title
  4. Copyright
  5. Contents
  6. Contributors
  7. Abbreviations list
  8. Foreword
  9. Preface
  10. 1 Aspects of multiple sclerosis that relate to experimental therapeutics
  11. 2 The pathology of multiple sclerosis
  12. 3 The immunology of multiple sclerosis
  13. 4 The genetics of multiple sclerosis
  14. 5 The epidemiology of multiple sclerosis
  15. 6 Measures of neurological impairment and disability in multiple sclerosis
  16. 7 Assessment of neuropsychological function in multiple sclerosis
  17. 8 Health-related quality of life assessment in multiple sclerosis
  18. 9 Measures of acute and chronic lesions visualized by conventional magnetic resonance imaging
  19. 10 Measures of magnetization transfer
  20. 11 Measurement of CNS atrophy
  21. 12 Axonal pathology in patients with multiple sclerosis
  22. 13 Imaging of gray matter lesions in multiple sclerosis
  23. 14 Functional imaging in multiple sclerosis
  24. 15 Diffusion imaging in multiple sclerosis
  25. 16 The use of MRI in multiple sclerosis clinical trials
  26. 17 Optical coherence tomography to monitor axonal and neuronal integrity in multiple sclerosis
  27. 18 The process of drug development and approval in the United States, the European Union, and Asia
  28. 19 Selection, interpretation, and development of end-points for multiple sclerosis clinical trials
  29. 20 The challenge of demonstrating long-term benefit of disease-modifying therapies in multiple sclerosis
  30. 21 The growing need for alternative clinical trial designs for multiple sclerosis
  31. 22 Ethical considerations in multiple sclerosis clinical trials
  32. 23 Pharmacogenomics and related discovery-driven approaches in multiple sclerosis
  33. 24 Neutralizing antibodies directed against biologic agents to treat multiple sclerosis
  34. 25 Interferon beta to treat multiple sclerosis
  35. 26 Glatiramer acetate to treat multiple sclerosis
  36. 27 Natalizumab to treat multiple sclerosis
  37. 28 Mitoxantrone to treat multiple sclerosis
  38. 29 Cladribine to treat multiple sclerosis
  39. 30 Fingolimod to treat multiple sclerosis
  40. 31 Dimethyl fumarate to treat multiple sclerosis
  41. 32 Alemtuzumab to treat multiple sclerosis
  42. 33 Daclizumab to treat multiple sclerosis
  43. 34 Laquinimod to treat multiple sclerosis
  44. 35 Teriflunomide to treat multiple sclerosis
  45. 36 High-dose methylprednisolone to treat multiple sclerosis
  46. 37 Use of immunosuppressants to treat multiple sclerosis
  47. 38 Intravenous immunoglobulin to treat multiple sclerosis
  48. 39 Plasma exchange treatment for CNS inflammatory demyelinating disease
  49. 40 Statins in multiple sclerosis
  50. 41 T-cell-based therapies for multiple sclerosis
  51. 42 B-cell-based therapies for multiple sclerosis
  52. 43 Sex hormones and other pregnancy-related factors with therapeutic potential in multiple sclerosis
  53. 44 Hematopoietic stem cell transplantation to treat multiple sclerosis
  54. 45 Mesenchymal stem cell transplantation to treat multiple sclerosis
  55. 46 Neuroprotection in multiple sclerosis
  56. 47 Combination therapy in multiple sclerosis
  57. 48 Dalfampridine in multiple sclerosis
  58. 49 Complementary and alternative treatments in multiple sclerosis
  59. 50 The role of chronic cerebrospinal venous insufficiency in multiple sclerosis
  60. 51 Disease-modifying therapy for multiple sclerosis in clinical practice
  61. 52 Treatment for patients with primary progressive multiple sclerosis
  62. 53 Diagnosis, pathogenesis, and treatment of neuromyelitis optica (NMO) spectrum disorders
  63. 54 Management of pediatric multiple sclerosis
  64. 55 Use of MRI in the clinical management of multiple sclerosis
  65. 56 Multiple sclerosis-associated fatigue
  66. 57 Management of spasticity
  67. 58 Management of bladder and sexual dysfunction in multiple sclerosis
  68. 59 Depression in multiple sclerosis
  69. 60 Assessment and treatment of pain disorders in multiple sclerosis
  70. 61 Management of medical comorbidities in patients with multiple sclerosis
  71. 62 Rehabilitation in multiple sclerosis
  72. Index